Moonwalk Biosciences at a glance
As of- [1] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), September 8, 2026
- [2] Total funding (reported): BioSpace, September 8, 2026
- [3] Lead investors: BioSpace, September 8, 2026
What Moonwalk Biosciences does
Moonwalk Biosciences develops adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases.[1] The company is based in South San Francisco and San Diego.[1] ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures joined that financing.[2] At launch it focused on precision epigenetic medicines.[2] The company later shifted to RNAi drugs because, Aravanis said, they would be a faster route to the clinic.[3] Its adipose-targeting chemistry is exclusively licensed from Suzhou Siran Biotechnology.[1] In preclinical studies, its drugs reduced body weight and fat mass while preserving lean muscle and without reducing food intake, the company says.[1] The money will take its lead candidate, MW101, into first-in-human studies in late 2027 and expand its pipeline of tissue-targeted siRNA drugs.[1]
Is this your company? Get featured or correct your listing →
Recent changes
- Sep 8, 2026Sep 8, 2026Raised $70M Series B BioSpace
- Sep 8, 2026Sep 8, 2026First reported total funding: ~$127M BioSpace
- Sep 8, 2026Sep 8, 2026New investor: Eli Lilly and Company BioSpace
- Sep 8, 2026Sep 8, 2026New investor: ARCH Venture Partners BioSpace
- Sep 8, 2026Sep 8, 2026New investor: Future Ventures BioSpace
Earlier changes (3)
- Sep 8, 2026Sep 8, 2026New investor: Alpha Wave Global BioSpace
- Sep 8, 2026Sep 8, 2026New investor: Khosla Ventures BioSpace
- Sep 8, 2026Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAi Pulse story
Funding history
1 equity event · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 8, 2026 | Series B | $70M | — | BioSpace |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
How Moonwalk Biosciences has been funded
Moonwalk launched with $57 million in seed and Series A financing led by Alpha Wave Ventures.[2] On September 8, 2026, Moonwalk closed an oversubscribed $70 million Series B.[1]
Investors and their roles
- Alpha Wave and YK Bioventures co-led the round, with Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures participating.[1]
Investors
Latest Pulse
Coverage Timeline
newest firstAll Coverage
Related Companies
Shared investors
Moonwalk Biosciences FAQ
Who invested in Moonwalk Biosciences?
Moonwalk launched with $57 million in seed and Series A financing led by Alpha Wave Ventures.[2]
Who founded Moonwalk Biosciences?
Moonwalk Biosciences was co-founded by Alex Aravanis, a former chief technology officer of Illumina, and Feng Zhang of the Broad Institute.[2]
Who is the CEO of Moonwalk Biosciences?
Aravanis is CEO.[1]
Where is Moonwalk Biosciences headquartered?
Moonwalk Biosciences is based in South San Francisco and San Diego.[1]
What does Moonwalk Biosciences do?
Moonwalk Biosciences develops adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases.[1]
How much has Moonwalk Biosciences raised?
Moonwalk Biosciences has raised at least $70M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $70M Series B in September 2026, reported by BioSpace. Debt financing, tender offers and secondary sales are not counted. BioSpace puts total funding at ~$127M (September 2026).
References
researched 2026-10-24Sources & methodologyshow
Where these figures come from
- BioSpaceresearch database2 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.